Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia

Thomas Lew, Mary Ann Anderson, Victor Lin, Sasanka Handunnetti, Neil Came, David Westerman, Wall Meaghan, Constantine Tam, Andrew W Roberts, John F Seymour